High-Dose Vitamin C and Oxalate Nephropathy:
An Early Safety Case That Deserves Attention
When high-dose vitamin C is used in a medical setting, potential clinical effects are only one part of the picture. Renal metabolism and safety also require careful consideration.
Vitamin C can be metabolized into oxalate in the human body. When oxalate accumulates and combines with calcium to form calcium oxalate crystals, those crystals may, under certain circumstances, deposit within the renal tubules and contribute to kidney injury.
What Happened in This Case?
This case report described a patient who already had significant renal and systemic disease and subsequently developed acute kidney dysfunction after receiving a large intravenous dose of ascorbic acid.
45 g
The Patient Had Primary Amyloidosis and Nephrotic Syndrome
The patient had primary amyloidosis and nephrotic syndrome, placing them in a population with pre-existing renal risk.
After receiving a single 45 g intravenous dose of ascorbic acid, the patient developed acute oliguric renal failure.
Extensive Calcium Oxalate Crystals Were Found in the Renal Tubules
Subsequent renal histopathology demonstrated extensive crystal deposition within the renal tubules, identified as calcium oxalate. Plasma ascorbate and oxalate concentrations were also elevated.
Why Can High-Dose Vitamin C Affect the Kidneys?
Ascorbic acid can be metabolized into oxalate, which is primarily eliminated through the kidneys. When oxalate load rises while renal clearance is impaired, the likelihood of calcium oxalate crystal formation and deposition may increase.
High-Dose Ascorbate
Large doses of vitamin C create an ascorbate exposure far above that of ordinary dietary intake or routine supplementation.
Oxalate Formation
A portion of ascorbate can be metabolized into oxalate within the body.
Calcium Oxalate Crystals
Oxalate can bind with calcium and form calcium oxalate crystals.
Renal Tubular Deposition
In certain high-risk situations, these crystals may deposit in the kidneys and contribute to tubular injury.
Greater Caution Is Needed in Patients with Renal Impairment
NIH ODS notes that high vitamin C intake may increase urinary oxalate excretion, particularly in people with kidney disease or existing hyperoxaluria. However, research on vitamin C and kidney stone risk is not entirely consistent.
How Should This Case Be Interpreted?
The value of this case lies in its safety warning, not in estimating the kidney risk for everyone who receives high-dose intravenous vitamin C.
It Was a Single Case
A single case report cannot determine the actual incidence of oxalate nephropathy among people receiving high-dose vitamin C.
The Patient Did Not Have Normal Renal Health
The patient already had primary amyloidosis and nephrotic syndrome, so the findings cannot simply be generalized to people with healthy kidney function.
The Case Still Provides an Important Warning
In people with impaired renal function or reduced capacity to process and excrete oxalate, large intravenous doses of ascorbate require more cautious evaluation.
A Serious Case Does Not Mean Every Patient Will Develop the Same Complication
This case does not show that everyone receiving high-dose intravenous vitamin C will develop oxalate nephropathy. It does show that renal risk should not be overlooked simply because vitamin C is classified as a vitamin.
How Does BMS Clinic View This Evidence?
High-dose intravenous vitamin C should not be considered only in terms of dose or potential clinical effects. The patient’s underlying kidney function and renal risk profile are equally important.
For patients with renal impairment, a history of kidney stones, or other factors that may affect oxalate metabolism or excretion, suitability for this type of medical support needs to be assessed on an individual basis.
BMS Clinic emphasizes professional medical assessment and appropriate monitoring when considering this type of supportive care, rather than applying the same infusion approach to every patient.
This page is provided for medical education and literature reference only. It is intended to help readers understand safety information concerning high-dose vitamin C and oxalate nephropathy and does not replace professional medical assessment or advice.
The study discussed is a single case report and cannot be used to estimate the actual incidence of kidney-related adverse events or generalised to all patients. However, it highlights a potential association between high-dose ascorbic acid, oxalate nephropathy, and acute kidney injury in certain high-risk individuals.
Before considering high-dose intravenous vitamin C, patients should undergo assessment and monitoring by qualified healthcare professionals, taking into account kidney function, history of kidney stones, and other relevant individual risk factors.
Learn More About Safety Assessment for High-Dose Vitamin C
This early case report highlights the importance of considering kidney function, a history of kidney stones, and oxalate-related risks when high-dose intravenous vitamin C is being considered. A single case cannot define the risk for the general population, but individuals with kidney disease or other risk factors should undergo an individual medical assessment before receiving this type of medical support.
References
Lawton JM, Conway LT, Crosson JT, Smith CL, Abraham PA. Acute oxalate nephropathy after massive ascorbic acid administration. Arch Intern Med. 1985;145(5):950–951.
National Institutes of Health, Office of Dietary Supplements. Vitamin C: Fact Sheet for Health Professionals.